Molecular Templates, Inc.

NasdaqCM:MTEM Stok Raporu

Piyasa değeri: US$2.8m

Molecular Templates Yönetim

Yönetim kriter kontrolleri 2/4

Molecular Templates CEO'su Eric Poma, Jan2009 tarihinde atandı, in görev süresi 15.83 yıldır. in toplam yıllık tazminatı $ 857.77K olup, şirket hissesi ve opsiyonları dahil olmak üzere 72.4% maaş ve 27.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.28% ine doğrudan sahiptir ve bu hisseler $ 7.74K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 7.3 yıldır.

Anahtar bilgiler

Eric Poma

İcra Kurulu Başkanı

US$857.8k

Toplam tazminat

CEO maaş yüzdesi72.4%
CEO görev süresi15.8yrs
CEO sahipliği0.3%
Yönetim ortalama görev süresi1.3yrs
Yönetim Kurulu ortalama görev süresi7.3yrs

Son yönetim güncellemeleri

Recent updates

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 30% Share Price Rise

Oct 10
There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 30% Share Price Rise

Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00

Aug 17
Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00

Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry

Jul 30
Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry

Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

Apr 03
Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

Dec 20
Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

Apr 17
There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Nov 16
What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

Aug 14
Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M

Aug 11

Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

Apr 29
Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?

Dec 30
Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?

Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Nov 25
Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?

Sep 22
Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?

News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts

Aug 15
News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts

Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

May 18
Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts

Mar 21
Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts

Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021

Feb 21
Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021

Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?

Jan 26
Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?

Molecular Templates updates on study of MT5111, plans breast cancer expansion cohort in 1H21

Dec 22

CEO Tazminat Analizi

Eric Poma'un ücretlendirmesi Molecular Templates'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$16m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$858kUS$621k

-US$8m

Sep 30 2023n/an/a

-US$26m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$60m

Dec 31 2022US$2mUS$600k

-US$93m

Sep 30 2022n/an/a

-US$81m

Jun 30 2022n/an/a

-US$87m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$4mUS$577k

-US$83m

Sep 30 2021n/an/a

-US$101m

Jun 30 2021n/an/a

-US$94m

Mar 31 2021n/an/a

-US$110m

Dec 31 2020US$5mUS$560k

-US$105m

Sep 30 2020n/an/a

-US$92m

Jun 30 2020n/an/a

-US$107m

Mar 31 2020n/an/a

-US$85m

Dec 31 2019US$2mUS$515k

-US$69m

Sep 30 2019n/an/a

-US$60m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$28m

Dec 31 2018US$4mUS$500k

-US$30m

Sep 30 2018n/an/a

-US$31m

Jun 30 2018n/an/a

-US$36m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$3mUS$448k

-US$24m

Tazminat ve Piyasa: Eric 'nin toplam tazminatı ($USD 857.77K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 653.16K ).

Tazminat ve Kazançlar: Eric 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Eric Poma (52 yo)

15.8yrs

Görev süresi

US$857,769

Tazminat

Dr. Eric E. Poma, Ph D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as its President. Dr. Poma founded Private Molecular in February 2009...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Eric Poma
CEO, Chief Scientific Officer & Director15.8yrsUS$857.77k0.28%
$ 7.7k
Jason Kim
President1.8yrsUS$579.24k0.097%
$ 2.7k
Kristen Quigley
Chief Operating Officer1.3yrsVeri yokVeri yok
Grace Kim
Chief Strategy Officer & Head of IR1.3yrsVeri yokVeri yok
Michelle Iwamoto-Fan
Senior Vice President & General Counselless than a yearVeri yokVeri yok
Joseph Phillips
Senior VP & Head of CMC Developmentno dataVeri yokVeri yok
Chris Moore
Senior VP and Head of Preclinical Development & Translational Medicineless than a yearVeri yokVeri yok

1.3yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: MTEM 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Eric Poma
CEO, Chief Scientific Officer & Director7.3yrsUS$857.77k0.28%
$ 7.7k
Michel Klein
Member of Scientific Advisory Boardno dataVeri yokVeri yok
David Hoffmann
Independent Director7.3yrsUS$59.29k0%
$ 0
Harold Selick
Independent Chairman7.3yrsUS$87.29k0.041%
$ 1.1k
Kevin Lalande
Independent Director7.3yrsUS$54.29k0%
$ 0
Corazon Sanders
Independent Director4.9yrsUS$49.29k0%
$ 0
Burkhard Jansen
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Neil Berinstein
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Gabriela Gruia
Director2.7yrsUS$561.35k0%
$ 0

7.3yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MTEM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.3 yıldır).